Cancer-Associated Thrombotic Microangiopathy; a Review Article Publisher



E Saffarieh ELHAM ; F Nokhostin FAHIMEH ; A Yousefnezhad AZADEH ; Sr Yousefi Sharami Seyedeh REYHANEH
Source: Journal of Renal Injury Prevention Published:2024

Abstract

Cancer-associated thrombotic microangiopathy (TMA) is a rare but is a serious complication that can occur in individuals with malignancy. It is characterized by widespread small blood vessel thrombosis (formation of blood clots) in various organs of the body, leading to organ damage and dysfunction. The exact mechanisms underlying cancer-associated TMA are not fully understood. However, several factors may contribute to its development. Cancer cells can release procoagulant substances that promote blood clot formation, since some tumors can directly invade blood vessels, leading to endothelial cell damage and activation of the coagulation system. Additionally, certain chemotherapeutic agents used in cancer treatment can have adverse effects on the endothelium, further increasing the risk of TMA. Clinically, cancer-associated TMA presents with a range of symptoms depending on the organs affected. Common manifestations include microangiopathic hemolytic anemia, thrombocytopenia, and organ-specific symptoms such as neurological deficits, renal dysfunction, or cardiac abnormalities. © 2024 Elsevier B.V., All rights reserved.